J. Jeffry Howbert,Muralikrishna Duvvuri,Robert Hershberg,Gregory Dietsch
申请号：
US14977129
公开号：
US20160331758A1
申请日:
2015.12.21
申请国别(地区):
US
年份:
2016
代理人:
摘要：
The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist which comprise a cyclodextrin.
